{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:11:52Z","timestamp":1793304712628,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["2T32CA009566-31"],"award-info":[{"award-number":["2T32CA009566-31"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA223662"],"award-info":[{"award-number":["R01 CA223662"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA223662"],"award-info":[{"award-number":["R01 CA223662"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Findings on racial differences in survival in multiple myeloma (MM) have been inconclusive. We assessed differences in outcomes between White and Black individuals among 639 newly diagnosed MM patients in the MM Research Foundation CoMMpass registry with baseline cytogenetic data. Survival curves were constructed using the Kaplan\u2013Meier method. Hazard ratios and 95% confidence intervals were derived from Cox proportional hazard regression models. Age, gender, and stage were similar between Whites (<jats:italic>n<\/jats:italic>\u2009=\u2009526) and Blacks (<jats:italic>n<\/jats:italic>\u2009=\u2009113). Blacks had inferior overall survival (OS) compared with Whites and were less likely to receive triplet therapies or frontline autologous stem cell transplant (ASCT). The following factors were significantly associated with inferior OS in multivariate analysis: higher international staging system (ISS) score, \u22651 or \u22652 high-risk cytogenetic abnormalities (HRCA), high-risk gene expression profile (GEP), and lack of ASCT. Multivariate analysis in the Black subset found that only lack of ASCT was significantly associated with inferior OS. The receipt of both triplet induction and ASCT only partly abrogated the effect of race on survival. HRCA did not track with survival in Blacks, emphasizing the need for race-specific risk prognostication schema to guide optimal MM therapy.<\/jats:p>","DOI":"10.1038\/s41408-020-00347-6","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:02:47Z","timestamp":1596805367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagoda","family":"Jasielec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-9081","authenticated-orcid":false,"given":"Spencer S.","family":"Langerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0875-263X","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-7244","authenticated-orcid":false,"given":"Brian C.-H.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"347_CR1","unstructured":"Howlader, N. et al. SEER Cancer Statistics Review, 1975\u20132017 (National Cancer Institute, Bethesda, MD, 2019)."},{"key":"347_CR2","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman, A. J. et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116, 5501\u20135506 (2010).","journal-title":"Blood"},{"key":"347_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","volume":"107","author":"O Landgren","year":"2006","unstructured":"Landgren, O. et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107, 904\u2013906 (2006).","journal-title":"Blood"},{"key":"347_CR4","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren, O. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468\u20131473 (2007).","journal-title":"Mayo Clin. Proc."},{"key":"347_CR5","first-page":"1860","volume":"98","author":"PA Konstantinopoulos","year":"2006","unstructured":"Konstantinopoulos, P. A., Pantanowitz, L. & Dezube, B. J. Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites\u2013the unknown role of underlying HIV infection. J. Natl Med. Assoc. 98, 1860\u20131861 (2006).","journal-title":"J. Natl Med. Assoc."},{"key":"347_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1022268103136","volume":"22","author":"M Benjamin","year":"2003","unstructured":"Benjamin, M., Reddy, S. & Brawley, O. W. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 22, 87\u201393 (2003).","journal-title":"Cancer Metastasis Rev."},{"key":"347_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0118-z","volume":"8","author":"CJ Smith","year":"2018","unstructured":"Smith, C. J., Ambs, S. & Landgren, O. Biological determinants of health disparities in multiple myeloma. Blood Cancer J. 8, 1\u20137 (2018).","journal-title":"Blood Cancer J"},{"key":"347_CR8","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1200\/JCO.2016.34.15_suppl.8022","volume":"34","author":"S Abouzaid","year":"2016","unstructured":"Abouzaid, S. et al. Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM). JCO 34, 8022\u20138022 (2016).","journal-title":"JCO"},{"key":"347_CR9","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi, S. et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 3, 2986\u20132994 (2019).","journal-title":"Blood Adv."},{"key":"347_CR10","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.V114.22.1395.1395","volume":"114","author":"N Shah","year":"2009","unstructured":"Shah, N. et al. Survival disparities between African-American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Blood 114, 1395\u20131395 (2009).","journal-title":"Blood"},{"key":"347_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0102-7","volume":"8","author":"S Ailawadhi","year":"2018","unstructured":"Ailawadhi, S. et al. Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 8, 67 (2018).","journal-title":"Blood Cancer J."},{"key":"347_CR12","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1002\/cam4.1246","volume":"6","author":"S Ailawadhi","year":"2017","unstructured":"Ailawadhi, S. et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER\u2010medicare analysis. Cancer Med. 6, 2876\u20132885 (2017).","journal-title":"Cancer Med."},{"key":"347_CR13","doi-asserted-by":"publisher","unstructured":"Fillmore, N. R. et al. With equal access, African Americans have superior survival compared to Caucasians with multiple myeloma: a VA study. Blood 2019000406, https:\/\/doi.org\/10.1182\/blood.2019000406 (2019).","DOI":"10.1182\/blood.2019000406"},{"key":"347_CR14","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1016\/j.clml.2019.04.019","volume":"19","author":"K Sweiss","year":"2019","unstructured":"Sweiss, K., Oh, A., Calip, G. S., Rondelli, D. & Patel, P. Superior survival in African American patients who underwent autologous stem cell transplantation for multiple myeloma. Clinical Lymphoma, Myeloma Leukemia 19, e506\u2013e511 (2019).","journal-title":"Clinical Lymphoma, Myeloma Leukemia"},{"key":"347_CR15","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/cncr.30747","volume":"123","author":"JR Schriber","year":"2017","unstructured":"Schriber, J. R. et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer 123, 3141\u20133149 (2017).","journal-title":"Cancer"},{"key":"347_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007087","volume":"13","author":"Z Manojlovic","year":"2017","unstructured":"Manojlovic, Z. et al. Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 13, e1007087 (2017).","journal-title":"PLoS Genet."},{"key":"347_CR17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/cncr.29160","volume":"121","author":"V Bhatnagar","year":"2015","unstructured":"Bhatnagar, V. et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer 121, 1064\u20131070 (2015).","journal-title":"Cancer"},{"key":"347_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/bloodadvances.2017010512","volume":"2","author":"ED Pulte","year":"2018","unstructured":"Pulte, E. D. et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2, 116\u2013119 (2018).","journal-title":"Blood Adv."},{"key":"347_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.91","volume":"5","author":"AJ Greenberg","year":"2015","unstructured":"Greenberg, A. J. et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 5, e271 (2015).","journal-title":"Blood Cancer J."},{"key":"347_CR20","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"347_CR21","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy, J. D. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"347_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19008","volume":"38","author":"S Mathura","year":"2020","unstructured":"Mathura, S. et al. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients. J. Clin. Oncol. 38, e19008 (2020). suppl; abstr.","journal-title":"J. Clin. Oncol."},{"key":"347_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.83","volume":"7","author":"M Binder","year":"2017","unstructured":"Binder, M. et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 7, e600 (2017).","journal-title":"Blood Cancer J."},{"key":"347_CR24","first-page":"4352","volume":"130","author":"V Bhatnagar","year":"2017","unstructured":"Bhatnagar, V. et al. FDA analysis of racial demographics in multiple myeloma trials. Blood 130, 4352\u20134352 (2017).","journal-title":"Blood"},{"key":"347_CR25","first-page":"207","volume":"56","author":"KC Abbott","year":"2001","unstructured":"Abbott, K. C. & Agodoa, L. Y. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin. Nephrol. 56, 207\u2013210 (2001).","journal-title":"Clin. Nephrol."},{"key":"347_CR26","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. JCO 28, 4976\u20134984 (2010).","journal-title":"JCO"},{"key":"347_CR27","doi-asserted-by":"crossref","unstructured":"Derman, B. A., Reiser, J., Basu, S. & Paner, A. Renal dysfunction and recovery following initial treatment of newly diagnosed multiple myeloma. Int. J. Nephrol. https:\/\/www.hindawi.com\/journals\/ijn\/2018\/4654717\/ (2018).","DOI":"10.1155\/2018\/4654717"},{"key":"347_CR28","unstructured":"American Cancer Society. Cancer Facts & Figures 2020 (American Cancer Society, 2020)."},{"key":"347_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.72","volume":"6","author":"N Bolli","year":"2016","unstructured":"Bolli, N. et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 6, e467 (2016).","journal-title":"Blood Cancer J."},{"key":"347_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0264-y","volume":"9","author":"V Yellapantula","year":"2019","unstructured":"Yellapantula, V. et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer J. 9, 1\u20139 (2019).","journal-title":"Blood Cancer J."},{"key":"347_CR31","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1177\/0022146510383838","volume":"51","author":"DR Williams","year":"2010","unstructured":"Williams, D. R. & Sternthal, M. Understanding racial\/ethnic disparities in health: sociological contributions. J. Health Soc. Behav. 51, S15\u2013S27 (2010).","journal-title":"J. Health Soc. Behav."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00347-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:33:23Z","timestamp":1670250803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00347-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"30 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.A.D., J.J., S.L., W.Z., A.J.J., and B.C.H.C. declare no competing interests. The University of Chicago is a member of the Multiple Myeloma Research Consortium.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"80"}}